BL-B01D1 clinical trials

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

This study is for people with a specific type of lung cancer that has stopped responding to treatment. Researchers are testing a new drug, Izalontamab Brengitecan, against standard chemotherapy to see which works better at controlling the cancer and helping people live longer.